Advanced Biomed Inc. (ADVB)
| Market Cap | 7.57M -99.1% |
| Revenue (ttm) | n/a |
| Net Income | 4.39M |
| EPS | 4.11 |
| Shares Out | 1.63M |
| PE Ratio | 1.25 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,048 |
| Open | 4.420 |
| Previous Close | 4.430 |
| Day's Range | 4.420 - 4.880 |
| 52-Week Range | 3.610 - 25.800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 26, 2026 |
About ADVB
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunost... [Read more]
Financial Performance
Financial StatementsNews
Advanced Biomed Inc trading halted, news pending
19:50 EST Advanced Biomed (ADVB) Inc trading halted, news pending
Advanced Biomed announces 1-for-20 share consolidation
Advanced Biomed (ADVB) announced a reverse stock split of the Company’s issued and outstanding common stock at a ratio of 1 for 20 shares, which will take effect at the…
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and commercializing innov...
Advanced Biomed enters into collaboration agreement with Chi-Mei Medical
Advanced Biomed (ADVB) announced the Company has entered into a clinical research collaboration agreement with Chi-Mei Medical Center to initiate a 120-case feasibility study designed to evaluate the ...
Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative b...
Advanced Biomed sells Hong Kong subsidiary for $23,000
Advanced Biomed (ADVB) entered into an agreement with an unrelated third party, Wei Ha Hui, pursuant to which the Company agreed to sell 100% of the issued and outstanding shares…
Advanced Biomed Inc. Announces Disposal of its Hong Kong Subsidiary
Tainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovat...
Advanced Biomed launches A+PerfusC System
Advanced Biomed (ADVB) announced the launch of its A+PerfusC system, a compact, all-in-one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. The A+Perf...
Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing inno...
Advanced Biomed files to sell 40M shares of common stock for holders
17:36 EDT Advanced Biomed (ADVB) files to sell 40M shares of common stock for holders
Sonoro Energy, Advanced BioCatalytics, and NexTier Energy Launch Strategic Collaboration to Advance Heavy Oil Recovery from Carbonate Reservoirs in the Middle East
May 5, 2025 – TheNewswire - Calgary, Alberta – Sonoro Energy Ltd. (“Sonoro” or the “Company” (TSX Venture: SNV) is pleased to announce that Sonoro, Advanced BioCatalytics Corporation, and NexTier Ener...
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering
Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and tre...
Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million
Advanced Biomed Inc. ADVB, has set terms for its initial public offering, in which the Taiwan-based biotechnology company focused on treating cancer is looking to raise up to $125 million. The company...